Accueil › Cancer du poumon › Montana › Billings
Essais cliniques pour Cancer du poumon à Billings, MT
13 études pour Cancer du poumon recherchent des participants dans et autour de Billings (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Recrutement en coursPhase 3
- Billings Clinic Cancer Center, Billings
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Billings Clinic Cancer Center, Billings
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Recrutement en coursPhase 3
- Billings Clinic Cancer Center, Billings
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Recrutement en coursPhase 3
- Billings Clinic Cancer Center, Billings
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Recrutement en coursPhase 3
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Recrutement en coursPhase 3
- St. Vincent Frontier Cancer Center, Billings
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Recrutement en coursPhase 3
- SCL Health - Montana, Billings
- SCL Health - Montana, Billings
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- Billings Clinic Cancer Center, Billings
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Recrutement en coursPhase 1/2
- Intermountain Health - St. Vincent Frontier Cancer Center, Billings
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- Billings Clinic Cancer Center, Billings
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- Billings Clinic Cancer Center, Billings
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2/3
- Billings Clinic Cancer Center, Billings
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, Billings
Essais pour Cancer du poumon dans d'autres villes
- Houston, TX78 études
- Boston, MA62 études
- New York City, NY60 études
- Los Angeles, CA45 études
- Washington, DC41 études
- Arlington, VA41 études
- Chicago, IL41 études
- Nashville, TN40 études
- Baltimore, MD40 études
- St. Louis, MO39 études
- Columbus, OH37 études
- Philadelphia, PA36 études
Autres études à Billings
- Cancer du poumon non à petites cellules17 études
- Cancer de la prostate15 études
- Cancer du sein10 études
- Cancer de l'ovaire9 études
- Mélanome7 études
- Leucémie lymphocytaire chronique7 études
- Cancer colorectal6 études
- Cancer du côlon6 études
- Cancer de la vessie6 études
- Leucémie aiguë myéloïde6 études
- Cancer rectal5 études
- Cancer de l'endomètre4 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.